Walker Maria C
Known title: DirectorCIK: 0001826519
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Five9 Gains Select ISV Partner Status With NovelVox. Five9 announced that NovelVox has achieved Select ISV Partner Status to help accelerate customer experience transformation in banking, credit unions, and healthcare. This partnership aims to integrate AI-driven voice solutions into Five9's platform for specific industry needs. The stock currently trades with a high beta, indicating higher volatility relative to the broader market.
Transaction History
| MPLT | ▲ Buy | Grant | 3,932 | $0 | 6/23/2026 | View on chart |
| FIVN | ▲ Buy | Grant | 8,972 | $0 | 5/20/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 6,294 | $0 | 10/27/2025 | View on chart |
| FIVN | ▲ Buy | Grant | 3,813 | $0 | 5/21/2024 | View on chart |
| FIVN | ▲ Buy | Grant | 7,626 | $0 | 5/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.